Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes

Gilling, Peter; Barber, Neil; Bidair, Mohamed; Anderson, Paul D.; Sutton, Mark; Aho, Tev; Kramolowsky, Eugene V.; Thomas, Andrew; Cowan, Barrett E.; Roehrborn, Claus G.

doi:10.1016/j.urology.2018.12.002

Cited by 52 publications

(34 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, IIEF and MSHQ-EjD scores remained stable in the cohort of men who underwent Aquablation®, compared to men who had decreased scores after undergoing TURP. By far, there has yet to be any reported case of ED with Aquablation® therapy [76, 77•].…”

Section: Newer Therapies For Bphmentioning

confidence: 99%

Minimizing Sexual Dysfunction in BPH Surgery

Leong

Patel

Ramasamy

2019

Curr Sex Health Rep

View full text Add to dashboard Cite

Purpose of Review To review the prevalence and risks of sexual dysfunction associated with current treatment options for benign prostatic hyperplasia and to characterize techniques and methods to manage postoperative sexual dysfunction-related side effects. Recent Findings Current surgical therapies available for the treatment of benign prostatic hyperplasia are associated with a substantial risk of both ejaculatory and erectile function. However, many of the novel minimally invasive treatment alternatives have demonstrated the ability to preserve postoperative sexual function to a better degree, all while providing significant relief of lower urinary tract symptoms in an equally safe and efficacious manner. Summary Benign prostatic hyperplasia remains a highly prevalent disease among the aging population. While surgical treatments are often necessary to relieve bothersome urinary symptoms, these procedures are associated with an increased risk of sexual dysfunction. As such, there has been an increased interest in the development of minimally invasive therapies, such as the UroLift®, Rezum®, and Aquablation®, with the hopes of achieving similar symptomatic relief while maintaining sexual function. Aside from reporting lower rates of sexual dysfunction, these procedures have also demonstrated comparable safety, durability, and efficacy to current gold standard therapies. Some procedures can even be performed in an outpatient setting, avoiding the need for general anesthesia altogether. Overall, an individualized, shared decision-making approach is necessary to determine the ideal treatment option for each patient.

show abstract

Section: Newer Therapies For Bphmentioning

confidence: 99%

Minimizing Sexual Dysfunction in BPH Surgery

Leong

Patel

Ramasamy

2019

Curr Sex Health Rep

View full text Add to dashboard Cite

show abstract

“…The overall complications associated with Aquablation were mostly low grade and acceptable. In the W‐I trial looking at small‐to‐moderate sized prostates, the rate of Clavien–Dindo ≥II events was less compared to similar sized prostates undergoing TURP . Our present analysis of the trials’ data, indicated that there was a statistically significant (14.9%) higher complication rate with greater blood loss in the W‐II cohort compared to W‐I, which is expected with larger prostate glands.…”

Section: Discussionmentioning

confidence: 55%

“…Since the first-in-man study of Aquablation for LUTS due to BPH published in 2016 [14], additional studies have supported the safety and effectiveness of Aquablation with short learning curves required to demonstrate that the technology was safe and effective [15,16]. These outcomes are potentially volume-independent, as explored in a recent subanalysis of the Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER II [W-II]) data, which found that Aquablation clinically normalised outcomes between patients of the <100 and >100 mL prostate cohorts [17].…”

Section: Introductionmentioning

confidence: 99%

Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objective To compare the outcomes of Aquablation in 30–80 mL prostates with those in 80–150 mL prostates. Surgical options, especially with short learning curves, are limited when treating large prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation (AquaBeam System, PROCEPT BioRobotics Inc., Redwood City, CA, USA) could solve this issue with global reproducibility, independent of prostate volume. Patients and Methods Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue (WATER [W‐I]; NCT02505919) is a prospective, double‐blind, multicentre, international clinical trial comparing Aquablation and transurethral resection of the prostate (TURP) for the treatment of LUTS/BPH in prostates between 30 and 80 mL. WATER II (W‐II; NCT03123250) is a prospective, multicentre, single‐arm international clinical trial of Aquablation in prostates between 80 and 150 mL. We compare baseline parameters and 12‐month outcomes in 116 W‐I and 101 W‐II study patients. Students’ t‐test or Wilcoxon tests were used for continuous variables and Fisher’s test for binary variables. Results The mean (SD) operative time was 33 (17) and 37 (13) min in W‐I and W‐II, respectively. Actual treatment time was 4 and 8 min in W‐I and W‐II, respectively. The mean change in the International Prostate Symptom Score was substantial averaging (at 12 months) 15.1 in W‐I and 17.1 in W‐II (P = 0.605). By 3 months, Clavien–Dindo grade ≥II events occurred in 19.8% of W‐I patients and 34.7% of W‐II patients (P = 0.468). Conclusion Aquablation clinically normalises outcomes between patients with 30–80 mL prostates and patients with 80–150 mL prostates treated for LUTS/BPH, with an expected increase in the risk of complications in larger prostates. Long‐term outcomes of procedure durability are needed.

show abstract

“…Transurethral resection of the prostate (TURP) is the most common surgery for benign prostatic hyperplasia (BPH) [1]. Despite its minimally invasive operation, bleeding still shows a common morbidity within and after surgery [2].…”

Section: Introductionmentioning

confidence: 99%

A Prospective Comparison of Three Strategies for Evaluating Blood Loss in Transurethral Resection of the Prostate

Yuan

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Objective. The aim of the current investigation is to develop a new strategy for evaluating blood loss in the process of transurethral resection of the prostate (TURP). Methods. 318 patients diagnosed with benign prostatic hyperplasia (BPH) that need TURP were enrolled in this study. Hospitalization information including age, height, weight, surgery time, prostate volume, hemoglobin (Hb) concentration, hematocrit (HCT) percentage, and red blood cell count (RBC) was evaluated for each patient. All statistical analysis drawing were conducted using R software. Results. Three methods were employed for calculating blood loss in TURP. Results from a new method display 0 missing value and got higher confidence (0 of 318, Poisson distribution, P < 0.001 ) compared with blood loss calculated with hemoglobin concentration (20.44%) and hematocrit percentage (19.18%). Also, the new method demonstrated narrow range (0.03~270.03 ml) and approximate normal distribution compared with blood loss calculated with hemoglobin concentration and hematocrit percentage. More importantly, the new method explained positive correlation with prostate volume ( R 2 = 0.138 , P < 0.001 ) and also surgery lasting time ( R 2 = 0.193 , P < 0.001 ). Conclusion. Methods developed for calculating blood loss in TURP in the current study displayed more accurate and reasonable evaluation of bleeding, which can guide the transfusion blood for patients.

show abstract

Randomized Controlled Trial of Aquablation versus Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia: One-year Outcomes

Cited by 52 publications

References 15 publications

Minimizing Sexual Dysfunction in BPH Surgery

Minimizing Sexual Dysfunction in BPH Surgery

Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30–80 and 80–150 mL prostates

A Prospective Comparison of Three Strategies for Evaluating Blood Loss in Transurethral Resection of the Prostate

Contact Info

Product

Resources

About